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S U M M A R Y 
Pancreatic ductal adenocarcinomas (PDAC), the fourth leading cause of cancer-
related deaths in the western world. High prevalence of a calcium-binding protein 
S100P has been shown to promote PDAC cancer, and several other types of 
aggressive cancer progression through its interaction with the receptor for 
advanced glycation end products (RAGE). This project aims to identify lead 
compounds from a bank of 93 newly designed compounds that attach to and 
prevent S100P from binding to and activating RAGE. Using an in-house produced 
human S100P, an improved enzyme linked immunosorbent assay (ELISA) was 
developed based on a previously published study. This assay was used to confirm 
the binding of S100P with RAGE, and to assess the efficacy of the lead compounds 
on migration of pancreatic cancer cells. In addition, MTS and LDH release assays, 
and Transwell cell migration and invasion studies were performed using 
pancreatic cancer cells to assess the viability, and migratory and invasive 
properties of these cells following treatment with the lead compounds.  
 
INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC), is a 
devastating disease resulting in approximately 
227,000 deaths annually worldwide Raimondi et al., 
(2009). There is currently no effective treatment for 
this disease which due mostly to the difficulty of 
detection at an early stage, and the inherent 
chemoresistance nature of cancer cells. Recent 
studies have shown that high levels of the calcium-
binding protein S100P found in PDAC enhances cell 
survival, proliferation and invasion through 
interactions with intracellular targets and via 
extracellular interaction with the receptor for 
advanced glycation end products (RAGE).  Previous 
in vivo studies have also shown that inhibition or 
silencing of S100P reduces tumour growth and 
metastasis, and enhances response to gemcitabine 
therapy.  As such, S100P has emerged as a 
promising biological target for novel anticancer drug 
design.  This study aims to identify S100P-RAGE 
inhibiting compounds from a library of newly designed 
compounds to aid development of a novel therapy for 
PDAC. 
MATERIALS AND METHODS 
Computational modelling of a small-molecule binding 
site in S100P was used in a virtual screen to identify 
lead compounds, predicted to bind S100P and inhibit 
its tumour-promoting effects.  An enzyme linked 
immunosorbent assay (ELISA), to detect S100P-
RAGE binding, was developed based on a published 
protocol by Padilla et al., (2014); 18 of all 93 lead 
compounds (purchased or synthesised in-house) 
which were screened for inhibition of S100P-RAGE 
interaction using this assay significantly inhibited 
S100P/RAGE interaction. These lead compounds 
were assessed for their effects on two human 
pancreatic cancer cell lines; S100P-overexpressing 
cells (BxPC-3) and cells expressing reduced amounts 
of S100P (Panc-1) using the MTS assay (CellTiter 
AQ, Promega, for metabolic activity) and LDH release 
assay (CytoTox, Promega, for cell toxicity). Transwell 
invasion assays were also performed on the cell lines 
to determine the effect of treatment with the lead 
compounds.  
RESULTS AND DISCUSSION 
BxPC-3 cells treated with lead compounds (figure 1) 
Ogbeni et al., (2015), for 48 hours, at 10µM, 
demonstrated a significant reduction (*P<0.0001) in 
cell invasion; whereas no effect was observed for the 
Panc-1 cells suggesting an S100P-specific 
mechanism (Figure 2). MTS and LDH release assays 
revealed that the compounds did not exhibit general 
cytotoxicity. Identified lead compounds will be further 
investigated for their effects on angiogenesis, and on 
the expression of key cell signalling proteins in 
pancreatic cancer cell.    
 
Figure 1. ELISA results from two novel compounds A. 
C54 and B. C56. Data are represented as the mean ± 
S.E.M, n=9 from 3 separate plates; significance by 
one-way ANOVA is denoted by *= p<0.05, and 
Dunnet’s posthoc test f= p<0.05 compared to (+ve) 
control. 
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Figure 2. Transwell invasion assay from five novel 
lead compounds. A) Invasion of BxPC-3 treated with 
lead compounds B) Invasion of Panc-1 cells exposed 
to lead compounds. Data are the means ± S.E.M of 
two independent experiments. Statistical significance 
was assessed by one-way ANOVA, *P<0.0001 vs. 
control.
CONCLUSIONS 
Results from this study has identified lead 
compounds with functional effects in S100P-
expressing pancreatic cancer cells and may enable 
further development of a potential therapy for 
pancreatic cancer. 
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